Stable Isotopically Labeled Intravenous Microdose Pharmacokinetic Trials as a Tool to Assess Absolute Bioavailability: Feasibility and Paradigm to Apply for Protein Kinase Inhibitors in Oncology

Detalles Bibliográficos
Autores principales: Roosendaal, Jeroen, Rosing, Hilde, Beijnen, Jos H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383911/
https://www.ncbi.nlm.nih.gov/pubmed/32573110
http://dx.doi.org/10.1002/cpdd.840
_version_ 1783563517527326720
author Roosendaal, Jeroen
Rosing, Hilde
Beijnen, Jos H.
author_facet Roosendaal, Jeroen
Rosing, Hilde
Beijnen, Jos H.
author_sort Roosendaal, Jeroen
collection PubMed
description
format Online
Article
Text
id pubmed-7383911
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-73839112020-07-27 Stable Isotopically Labeled Intravenous Microdose Pharmacokinetic Trials as a Tool to Assess Absolute Bioavailability: Feasibility and Paradigm to Apply for Protein Kinase Inhibitors in Oncology Roosendaal, Jeroen Rosing, Hilde Beijnen, Jos H. Clin Pharmacol Drug Dev Commentary John Wiley and Sons Inc. 2020-06-22 2020-07 /pmc/articles/PMC7383911/ /pubmed/32573110 http://dx.doi.org/10.1002/cpdd.840 Text en © 2020 The Authors. Clinical Pharmacology in Drug Development published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Roosendaal, Jeroen
Rosing, Hilde
Beijnen, Jos H.
Stable Isotopically Labeled Intravenous Microdose Pharmacokinetic Trials as a Tool to Assess Absolute Bioavailability: Feasibility and Paradigm to Apply for Protein Kinase Inhibitors in Oncology
title Stable Isotopically Labeled Intravenous Microdose Pharmacokinetic Trials as a Tool to Assess Absolute Bioavailability: Feasibility and Paradigm to Apply for Protein Kinase Inhibitors in Oncology
title_full Stable Isotopically Labeled Intravenous Microdose Pharmacokinetic Trials as a Tool to Assess Absolute Bioavailability: Feasibility and Paradigm to Apply for Protein Kinase Inhibitors in Oncology
title_fullStr Stable Isotopically Labeled Intravenous Microdose Pharmacokinetic Trials as a Tool to Assess Absolute Bioavailability: Feasibility and Paradigm to Apply for Protein Kinase Inhibitors in Oncology
title_full_unstemmed Stable Isotopically Labeled Intravenous Microdose Pharmacokinetic Trials as a Tool to Assess Absolute Bioavailability: Feasibility and Paradigm to Apply for Protein Kinase Inhibitors in Oncology
title_short Stable Isotopically Labeled Intravenous Microdose Pharmacokinetic Trials as a Tool to Assess Absolute Bioavailability: Feasibility and Paradigm to Apply for Protein Kinase Inhibitors in Oncology
title_sort stable isotopically labeled intravenous microdose pharmacokinetic trials as a tool to assess absolute bioavailability: feasibility and paradigm to apply for protein kinase inhibitors in oncology
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383911/
https://www.ncbi.nlm.nih.gov/pubmed/32573110
http://dx.doi.org/10.1002/cpdd.840
work_keys_str_mv AT roosendaaljeroen stableisotopicallylabeledintravenousmicrodosepharmacokinetictrialsasatooltoassessabsolutebioavailabilityfeasibilityandparadigmtoapplyforproteinkinaseinhibitorsinoncology
AT rosinghilde stableisotopicallylabeledintravenousmicrodosepharmacokinetictrialsasatooltoassessabsolutebioavailabilityfeasibilityandparadigmtoapplyforproteinkinaseinhibitorsinoncology
AT beijnenjosh stableisotopicallylabeledintravenousmicrodosepharmacokinetictrialsasatooltoassessabsolutebioavailabilityfeasibilityandparadigmtoapplyforproteinkinaseinhibitorsinoncology

Ejemplares similares